Comparable stake leader
ARMISTICE CAPITAL, LLC
SEC ownership of BELLICUM PHARMACEUTICALS, INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001358403.
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
1/10
Latest evidence
30 Jun 2025
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ARMISTICE CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 10
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ARMISTICE CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001358403
- Issuer location
- Houston, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BELLICUM PHARMACEUTICALS, INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
1/10
Latest evidence
30 Jun 2025
13D/G
3/4/5
Lead comparable stake: 10%
9 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-8 of 10 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 10%.
1 of 10 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 1
ARMISTICE CAPITAL, LLC
10%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 10 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
10%
|
$1,153,951
1,078,459 shares
|
$0 | 30 Jun 2025 |
| BAKER BROS. ADVISORS LP |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
—
16,386,662 shares
mixed-class rows
|
— | 22 Nov 2023 |
| Richard A. Fair |
3/4/5
President and CEO, Director
|
—
class O/S missing
|
—
400,000 shares
|
— | 15 Aug 2022 |
| Charity Scripture |
3/4/5
Chief Development Officer
|
—
class O/S missing
|
—
250,000 shares
|
— | 15 Aug 2022 |
| Jon P. Stonehouse |
3/4/5
Director
|
—
class O/S missing
|
—
204,086 shares
|
— | 03 Jan 2023 |
| Reid M. Huber |
3/4/5
Director
|
—
class O/S missing
|
—
146,951 shares
|
— | 03 Jan 2023 |
| Stephen Davis |
3/4/5
Director
|
—
class O/S missing
|
—
136,854 shares
|
— | 03 Jan 2023 |
| Judith Klimovsky V |
3/4/5
Director
|
—
class O/S missing
|
—
110,098 shares
|
— | 03 Jan 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 15 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to BELLICUM PHARMACEUTICALS, INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Stephen Davis
Net 12M change
$0
Latest report
22 Nov 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Stephen Davis | Director | Mixed | 03 Jan 2023 | |||
| Jon P. Stonehouse | Director | Mixed | 03 Jan 2023 | |||
| James F. Brown | Director | Mixed | 04 Jan 2022 | |||
| Reid M. Huber | Director | Mixed | 03 Jan 2023 | |||
| Richard A. Fair | President and CEO, Director | Mixed | 15 Aug 2022 | |||
| Charity Scripture | Chief Development Officer | Mixed | 15 Aug 2022 | |||
| James M. Daly | Director | Mixed | 03 Jan 2023 | |||
| Charles S. Grass | Principal Accounting Officer | Mixed | 11 May 2021 | |||
| Judith Klimovsky V | Director | Mixed | 03 Jan 2023 | |||
| BAKER BROS. ADVISORS LP | 10%+ Owner | Mixed | 22 Nov 2023 |
Recent insider transactions for BELLICUM PHARMACEUTICALS, INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.